Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable
Source: SeekingAlpha
2026-02-27 15:13:54 ET
Novo Nordisk ( NVO ) has experienced a hefty sell-off following worse-than-expected trial results of their weight loss drug CagriSema. Simultaneously, their main competitor, Eli Lilly ( LLY ), managed to keep or even expand their edge....
Read the full article on Seeking Alpha
For further details see:
Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable
Novo Nordisk - Class B
NASDAQ: NONOF
NONOF Trading
-1.04% G/L:
$36.285 Last:
15,464 Volume:
$35.01 Open:
NONOF Latest News
NONOF Stock Data
$217,715,792,624
1,607,906,287
N/A
1546
N/A
Biotechnology & Life Sciences
Healthcare
DK
Bagsvaerd
